Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated May 23, 2016 (10 years ago)

Nitrofurantoin Oral Suspension

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Dissolution Specifications

Cause type: Dissolution failure

The tablet or capsule did not dissolve within specification. Dissolution controls how much drug the body absorbs; a failure can change the effective dose. All dissolution failure recalls.

What was recalled

Nitrofurantoin Oral Suspension, USP, 25 mg/5 mL, FOR ORAL USE ONLY, URINARY TRACT ANTIBACTERIAL, Rx Only , 240 mL bottle, Dist. by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Mfg. by: Sun Pharmaceutical Industries, Inc., Bryan, Ohio 43506, NDC 57664-239-32

Affected NDC 57664-0239-32

Compare with the code on your package — it is the most precise check available.

Drug: Nitrofurantoin

Recalling firm
Nostrum Laboratories, Inc.
NDC code
57664-239-32
Origin
OH, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1030-2016 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Nitrofurantoin recalls

See all
Class III · Low risk

Nitrofurantoin Capsules

Failed Dissolution Specifications: Nitrofurantoin Capsules recalled due to dissolution failure at 0-time of the repackaged lot. Drug release results were above specification at 0-time.

Terminated Dissolution failure American Health Packaging NDC 68084-446-11 D-0880-2022

Other recalls by Nostrum Laboratories, Inc.

All 2016 recalls
Class II · Moderate risk

Sucralfate Tablets

CGMP Deviations: The recalling firm filed for Chapter 11 in September 2024. As a result, it cannot monitor the quality program and hence cannot assure that products meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess, rendering the products adulterated.

Ongoing cGMP deviation Nostrum Laboratories, Inc. NDC 29033-0003-01 D-0547-2025